| 328 | Parkinson disease |
| 278 | Humans |
| 196 | Male |
| 185 | Nervous system diseases |
| 182 | Female |
| 155 | Aged |
| 150 | Middle Aged |
| 139 | Human |
| 83 | Adult |
| 82 | Parkinson's disease |
| 79 | Animals |
| 66 | Treatment |
| 63 | Parkinson Disease (drug therapy) |
| 58 | Parkinson Disease (genetics) |
| 50 | Aged, 80 and over |
| 46 | Parkinson Disease (physiopathology) |
| 41 | Parkinson Disease (complications) |
| 39 | Dopamine |
| 38 | Animal |
| 36 | Parkinson Disease (pathology) |
| 35 | Chemotherapy |
| 33 | Parkinson Disease (metabolism) |
| 33 | Levodopa |
| 30 | Antiparkinson agent |
| 29 | Treatment Outcome |
| 28 | Parkinsonism |
| 28 | Parkinson Disease (therapy) |
| 27 | Severity of Illness Index |
| 27 | Mutation |
| 27 | Case-Control Studies |
| 25 | Emission tomography |
| 24 | Parkinson Disease (diagnosis) |
| 24 | Mice |
| 23 | Toxicity |
| 23 | Dyskinesia |
| 23 | Antiparkinson Agents (therapeutic use) |
| 22 | Rat |
| 22 | Parkinson Disease (epidemiology) |
| 22 | Double-Blind Method |
| 22 | Deep brain stimulation |
| 21 | Disease Progression |
| 21 | Corpus striatum |
| 20 | Parkinson Disease (psychology) |
| 20 | Genetics |
| 20 | Cohort Studies |
| 19 | Monkey |
| 19 | Exploration |
| 19 | Disease Models, Animal |
| 19 | Comparative study |
| 19 | Canada |
| 18 | Risk Factors |
| 18 | Protein-Serine-Threonine Kinases (genetics) |
| 18 | Brain (metabolism) |
| 17 | United States |
| 17 | Risk factor |
| 17 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 17 | Immunohistochemistry |
| 17 | Dopamine (metabolism) |
| 16 | Retrospective Studies |
| 16 | Positron |
| 16 | Parkinson Disease (diagnostic imaging) |
| 16 | Levodopa (therapeutic use) |
| 16 | Follow-Up Studies |
| 15 | Time Factors |
| 15 | Subthalamic nucleus |
| 15 | Locus niger |
| 15 | Genotype |
| 15 | D2 Dopamine receptor |
| 14 | Positron emission tomography |
| 14 | Phenotype |
| 14 | Levodopa (adverse effects) |
| 14 | Encephalon |
| 14 | Dopamine agonist |
| 14 | Dementia |
| 14 | Cognition |
| 14 | Antiparkinson Agents (adverse effects) |
| 14 | Agonist |
| 13 | deep brain stimulation |
| 13 | Prognosis |
| 13 | Parkinson Disease (etiology) |
| 13 | Neuropsychological Tests |
| 13 | Alzheimer disease |
| 12 | Surgery |
| 12 | Rats |
| 12 | Mutation (genetics) |
| 12 | Genetic Predisposition to Disease |
| 12 | Elderly |
| 12 | Depression |
| 12 | Brain (pathology) |
| 12 | Basal ganglion |
| 11 | Tremor |
| 11 | Tomography, Emission-Computed |
| 11 | Surveys and Questionnaires |
| 11 | Randomized Controlled Trials as Topic |
| 11 | Longitudinal Studies |
| 11 | Cognitive disorder |
| 10 | levodopa |
| 10 | Parkinson Disease (surgery) |
| 10 | Neuron |
| 10 | Magnetic Resonance Imaging |
| 10 | Diagnosis |
| 10 | Degeneration |
| 10 | Complication |
| 10 | Behavior |
| 10 | Animal model |
| 10 | Age of Onset |
| 10 | Adolescent |
| 9 | dyskinesia |
| 9 | alpha-Synuclein (genetics) |
| 9 | Transplantation |
| 9 | Psychotropic |
| 9 | Prospective Studies |
| 9 | Polymorphism, Single Nucleotide |
| 9 | Pathogenesis |
| 9 | Parkinson Disease, Secondary (chemically induced) |
| 9 | Pallidum |
| 9 | Long term |
| 9 | Gene |
| 9 | Dose-Response Relationship, Drug |
| 9 | Disability Evaluation |
| 9 | Brain (diagnostic imaging) |
| 8 | Review |
| 8 | Public health |
| 8 | Prevalence |
| 8 | Predictive Value of Tests |
| 8 | Positron-Emission Tomography |
| 8 | Pedigree |
| 8 | Neurons (metabolism) |
| 8 | Motor control |
| 8 | Mice, Transgenic |
| 8 | Mice, Inbred C57BL |
| 8 | Medicine |
| 8 | Medical screening |
| 8 | Macaca fascicularis |
| 8 | Genome-Wide Association Study |
| 8 | Functional Laterality |
| 8 | Evolution |
| 8 | Dihydroxyphenylalanine (analogs & derivatives) |
| 8 | Dementia (complications) |
| 8 | Degenerative disease |
| 8 | Corpus Striatum (metabolism) |
| 8 | Corpus Striatum (diagnostic imaging) |
| 8 | Cognition Disorders (etiology) |
| 8 | Clinical trial |
| 8 | Clinical management |
| 8 | Cells, Cultured |
| 7 | parkinsonism |
| 7 | genetics |
| 7 | alpha-Synuclein (metabolism) |
| 7 | Speech |
| 7 | Risk |
| 7 | Reproducibility of Results |
| 7 | Quality of Life |
| 7 | Putamen |
| 7 | Proportional Hazards Models |
| 7 | Pathophysiology |
| 7 | Parkinson Disease (mortality) |
| 7 | PB |
| 7 | Neurons (pathology) |
| 7 | Neurology |
| 7 | Models |
| 7 | Modeling |
| 7 | Lesion |
| 7 | Haplotypes |
| 7 | Genetic determinism |
| 7 | Genetic Predisposition to Disease (genetics) |
| 7 | Gene Frequency |
| 7 | Family study |
| 7 | Epidemiology |
| 7 | Drug combination |
| 7 | Drug Therapy, Combination |
| 7 | Dopaminergic neuron |
| 7 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
| 7 | Dementia (pathology) |
| 7 | Deep Brain Stimulation (methods) |
| 7 | Case study |
| 7 | Biological receptor |
| 7 | Autopsy |
| 7 | Analysis of Variance |
| 7 | Age Factors |
| 6 | tau Proteins (genetics) |
| 6 | dopamine |
| 6 | Rats, Sprague-Dawley |
| 6 | Putamen (metabolism) |
| 6 | Psychomotor Performance (physiology) |
| 6 | Nuclear magnetic resonance imaging |
| 6 | Neurons (drug effects) |
| 6 | Multicenter study |
| 6 | Molecular Sequence Data |
| 6 | Models, Biological |
| 6 | International Cooperation |
| 6 | Guam |
| 6 | Guam Parkinson dementia |
| 6 | Glial cell line derived neurotrophic factor |
| 6 | Genetic disease |
| 6 | Gene expression |
| 6 | Fluorine Radioisotopes |
| 6 | Familial disease |
| 6 | Electrodes, Implanted |
| 6 | Dystonia |
| 6 | Double blind study |
| 6 | Dopamine receptor |
| 6 | Dopamine Agonists (therapeutic use) |
| 6 | Deep Brain Stimulation |
| 6 | Corpus Striatum (pathology) |
| 6 | Comorbidity |
| 6 | Cognition Disorders (diagnosis) |
| 6 | Child |
| 6 | Cell death |
| 6 | Catechol O-methyltransferase |
| 6 | Canada (epidemiology) |
| 6 | Association |
| 6 | Amino Acid Sequence |
| 6 | Age of onset |
| 5 | Young Adult |
| 5 | United States (epidemiology) |
| 5 | Turnover |
| 5 | Treatment efficiency |
| 5 | Tolcapone |
| 5 | Subthalamic Nucleus (physiology) |
| 5 | Selegiline (therapeutic use) |
| 5 | Safety |
| 5 | Psychiatric Status Rating Scales |
| 5 | Primates |
| 5 | Positron-Emission Tomography (methods) |
| 5 | Polymorphism, Single Nucleotide (genetics) |
| 5 | Photic Stimulation |
| 5 | Perception |
| 5 | Parkinsonian Disorders (physiopathology) |
| 5 | Parkinson Disease (enzymology) |
| 5 | PET |
| 5 | Oxidative stress |
| 5 | Outcome Assessment (Health Care) |
| 5 | Oral administration |
| 5 | Nigrostriatal pathway |
| 5 | Neurotoxin |
| 5 | Neurons (physiology) |
| 5 | Nerve Tissue Proteins (genetics) |
| 5 | Multiple system atrophy |
| 5 | Mouse |
| 5 | Motor system disorder |
| 5 | Motor Activity |
| 5 | Mitochondria |
| 5 | Mice, Knockout |
| 5 | Metabolism |
| 5 | Mesencephalon (pathology) |
| 5 | Memory |
| 5 | Lewy body |
| 5 | Levodopa (administration & dosage) |
| 5 | Language disorder |
| 5 | Incidence |
| 5 | Impulse control disorder |
| 5 | Genetic Association Studies |
| 5 | Fluorodopa(18F) |
| 5 | Family Health |
| 5 | Evaluation scale |
| 5 | Essential Tremor (genetics) |
| 5 | Environment |
| 5 | Electrocardiography |
| 5 | Dopaminergic Neurons (metabolism) |
| 5 | Dopamine Agonists (adverse effects) |
| 5 | Dopamine Agents (therapeutic use) |
| 5 | Development |
| 5 | DNA Mutational Analysis |
| 5 | Corpus Striatum (drug effects) |
| 5 | Cerebral disorder |
| 5 | Central nervous system |
| 5 | Brain (vertebrata) |
| 5 | Brain (physiopathology) |
| 5 | Blotting, Western |
| 5 | Astrocyte |
| 5 | Arctic Regions (epidemiology) |
| 5 | Antiparkinson Agents (administration & dosage) |
| 5 | Amyotrophic lateral sclerosis |
| 5 | American |
| 5 | Advanced stage |
| 5 | Activities of Daily Living |
| 4 | treatment |
| 4 | transplantation |
| 4 | stars: neutron |
| 4 | methods: statistical |
| 4 | hippocampus |
| 4 | dystonia |
| 4 | depression |
| 4 | climate change |
| 4 | Uptake |
| 4 | Ubiquitin-Protein Ligases (metabolism) |
| 4 | UPDRS |
| 4 | Tyrosine 3-monooxygenase |
| 4 | Tomography, X-Ray Computed |
| 4 | Tetrabenazine (analogs & derivatives) |
| 4 | Technique |
| 4 | TCDD |
| 4 | Survival |
| 4 | Steroid |
| 4 | Sequence Analysis, DNA |
| 4 | Senescence |
| 4 | Ropinirole |
| 4 | Risk Assessment (methods) |
| 4 | Regression Analysis |
| 4 | Reference Values |
| 4 | Radiopharmaceuticals |
| 4 | Raclopride |
| 4 | RNA, Messenger (metabolism) |
| 4 | RNA, Messenger (genetics) |
| 4 | Questionnaire |
| 4 | Putamen (diagnostic imaging) |
| 4 | Psychosis |
| 4 | Psychometrics |
| 4 | Protein-Serine-Threonine Kinases (metabolism) |
| 4 | Protein Kinases (metabolism) |
| 4 | Prevention |
| 4 | Postoperative Complications |
| 4 | Polymorphism |
| 4 | Placebo |
| 4 | Parkinson’s disease |
| 4 | Oxidopamine |
| 4 | Oxidative Stress |
| 4 | Nitrophenols |
| 4 | Neuroprotective Agents (therapeutic use) |
| 4 | Neuroprotective Agents (pharmacology) |
| 4 | Neural Pathways (physiopathology) |
| 4 | Movement Disorders (physiopathology) |
| 4 | Motor Activity (drug effects) |
| 4 | Mitochondria (metabolism) |
| 4 | Metamfetamine |
| 4 | Mental Status Schedule |
| 4 | Manganese |
| 4 | MPTP |
| 4 | MC |
| 4 | Lewy Body Disease (genetics) |
| 4 | Levodopa (pharmacology) |
| 4 | Levodopa (metabolism) |
| 4 | Instrumentation therapy |
| 4 | Instrumental stimulation |
| 4 | Indoles (adverse effects) |
| 4 | In vivo |
| 4 | Implant |
| 4 | Immunoblotting assay |
| 4 | Identification |
| 4 | Huntington disease |
| 4 | Heterozygote |
| 4 | Globus Pallidus (surgery) |
| 4 | Genomics |
| 4 | Genetic Variation |
| 4 | Gene Expression Regulation |
| 4 | Gait Disorders, Neurologic (etiology) |
| 4 | Fluctuations |
| 4 | Experimental disease |
| 4 | Evaluation |
| 4 | European Continental Ancestry Group (genetics) |
| 4 | Essential |
| 4 | Enzyme inhibitor |
| 4 | Electrical stimulus |
| 4 | Early |
| 4 | EIC |
| 4 | Dyskinesia, Drug-Induced (physiopathology) |
| 4 | Dopaminergic Neurons (pathology) |
| 4 | Dopamine Agents (pharmacology) |
| 4 | Dopamine (physiology) |
| 4 | Diagnosis, Differential |
| 4 | Dementia (diagnosis) |
| 4 | DNA |
| 4 | Coordination |
| 4 | Computer Simulation |
| 4 | Cognition (physiology) |
| 4 | Child, Preschool |
| 4 | Cell Survival |
| 4 | Cell Line |
| 4 | Catecholamine |
| 4 | Carrier protein |
| 4 | Brain Mapping |
| 4 | Body movement |
| 4 | Biological activity |
| 4 | B[a]P |
| 4 | Attention |
| 4 | Atrophy |
| 4 | Anatomic pathology |
| 4 | Alzheimer's disease |
| 4 | Alzheimer Disease (pathology) |
| 4 | Aging (psychology) |
| 4 | Addiction |
| 4 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
| 3 | surveys |
| 3 | supraventricular tachycardia |
| 3 | subthalamic nucleus |
| 3 | schizophrenia |
| 3 | rating scales |
| 3 | rat |
| 3 | pulsars: general |
| 3 | progressive supranuclear palsy |
| 3 | prognosis |
| 3 | positron emission tomography (PET) |
| 3 | phylogeography |
| 3 | pharmacokinetics |
| 3 | oxidative stress |
| 3 | mitochondrial DNA |
| 3 | large‐scale structure of Universe |
| 3 | dopa‐responsive dystonia |
| 3 | dopamine agonists |
| 3 | dementia |
| 3 | cosmology: observations |
| 3 | clinimetrics |
| 3 | clinical trial |
| 3 | Wolff Parkinson White syndrome |
| 3 | Vision |
| 3 | Vesicular monoamine transporter |
| 3 | Vesicular Transport Proteins (genetics) |
| 3 | Uric acid |
| 3 | Ubiquinone (administration & dosage) |
| 3 | UPDRS = Unified Parkinson's Disease Rating Scale |
| 3 | Tyrosine 3-Monooxygenase (metabolism) |
| 3 | Tomography, Emission-Computed, Single-Photon |
| 3 | Thiazoles (therapeutic use) |
| 3 | Thiazoles (adverse effects) |
| 3 | Thalamus |
| 3 | TLC |
| 3 | TCDF |
| 3 | Symptomatology |
| 3 | Subthalamic Nucleus (surgery) |
| 3 | Subthalamic Nucleus (physiopathology) |
| 3 | Subthalamic Nucleus (drug effects) |
| 3 | Substantia Nigra (physiopathology) |
| 3 | Substantia Nigra (pathology) |
| 3 | Substantia Nigra (metabolism) |
| 3 | Structure activity relation |
| 3 | Stroke |
| 3 | Storage |
| 3 | Stereotaxic surgery |
| 3 | Signal Transduction (drug effects) |
| 3 | Sex Factors |
| 3 | Sequence Alignment |
| 3 | Selegiline |
| 3 | Rivastigmine |
| 3 | Risk Assessment |
| 3 | Retina |
| 3 | Restless legs syndrome |
| 3 | Regulation(control) |
| 3 | Receptors, Dopamine D2 (metabolism) |
| 3 | Reaction Time |
| 3 | Rasagiline |
| 3 | Rapid eye movement sleep |
| 3 | Radionuclide Imaging |
| 3 | REM Sleep Behavior Disorder (diagnosis) |
| 3 | REM Sleep Behavior Disorder (complications) |
| 3 | Quality of life |
| 3 | Psychomotor Performance |
| 3 | Protozoan Proteins (genetics) |
| 3 | Protein |
| 3 | Protein Kinases (genetics) |
| 3 | Protein Deglycase DJ-1 |
| 3 | Prospective |
| 3 | Proprioception |
| 3 | Posture |
| 3 | Postural Balance |
| 3 | Population Surveillance |
| 3 | Plasticity |
| 3 | Piperidines (pharmacology) |
| 3 | Pigment Epithelium of Eye (transplantation) |
| 3 | Phylogeny |
| 3 | Photon |
| 3 | Phosphorylation |
| 3 | Pesticides |
| 3 | Pergolide |
| 3 | Peptidomimetic compound |
| 3 | Pathology |
| 3 | Parkinsonian Disorders (diagnostic imaging) |
| 3 | Parkinson Disease (immunology) |
| 3 | Parkinson Disease (blood) |
| 3 | Parkin |
| 3 | Paraquat |
| 3 | PMR |
| 3 | PCB |
| 3 | Organ Specificity |
| 3 | Ontario (epidemiology) |
| 3 | Oncogene Proteins (genetics) |
| 3 | Odds Ratio |
| 3 | Neurotrophic factor |
| 3 | Neuroprotective agent |
| 3 | Neuroprotection |
| 3 | Neurons (chemistry) |
| 3 | Neurological disorder |
| 3 | Neuroleptics |
| 3 | Neuroleptic |
| 3 | Neurofibrillary tangle |
| 3 | Neurodegenerative Diseases (metabolism) |
| 3 | Multivariate Analysis |
| 3 | Movement Disorders (therapy) |
| 3 | Movement Disorders (etiology) |
| 3 | Motricity |
| 3 | Motion |
| 3 | Motility disorder |
| 3 | Monoamine Oxidase Inhibitors (therapeutic use) |
| 3 | Molecular Chaperones (genetics) |
| 3 | Modification |
| 3 | Models, Statistical |
| 3 | Microglia (drug effects) |
| 3 | Microelectrode |
| 3 | Mexico |
| 3 | Metaanalysis |
